Objective To study the olfactory function in Chinese patients with Parkinsons disease (PD) and its application in diagnosis and differential diagnosis of Parkinsonism Methods The thresholds of olfactory detection and identification were determined by using “five odors olfactory detection arrays” provided by Chinese Academy of Sciences for the 50 PD patients, 30 healthy controls, 30 persons with other neurological diseases, and 7 atypical Parkinsons disease patients Results The olfactory detection and identification thresholds of PD patients were significantly higher than those of the normal controls and than those with other neurological diseases But the olfactory identification threshold of PD patients was significantly higher than those with atypical Parkinsons disease The sensitivity and specificity in the olfactory test were 74 0% and 91 7%, respectively by combining the olfactory detection and identification thresholds together Conclusions The olfactory function was found significantly decreased in PD patients The olfactory test might play an important role in the diagnosis and differentiated diagnosis of PD

Objective To investigate the relationship between serum uric acid (UA)levels and Parkinson's disease (PD) risk under specific lifestyle exposures.Methods Case-control study was used.Three hundred and ninety-seven PD cases and the same number of controls with matched age and gender were selected.Demographic and exposure information was collected by face-to-face interview,and blood biochemistry studies tested.Logistic regression model was used to analyze the association of PD risk with UA levels or enviromental factors.Results The highest value of UA levels was associated with a decreased PD risk compared to the lowest value (OR =0.39,95％ CI 0.25-0.63) in both male and female groups.This association was significant among nonsmokers (OR =0.52,95％ CI 0.32-0.76),nondrinkers (OR =0.4,95％ CI 0.34-0.70),and persons taking exercise more than 1 houre a day (OR =0.51,95％ CI 0.35-0.74).But no significant association was affected in the subjects with smoking or drinking history and those with less exercise (＜ 1 hour a day).Conclusion We confirmed that higher UA levels were associated with lower PD risk in Chinese population,and some lifestyles may modify the protection effect of serum UA.

GBA1 is one of the common risk genes of Parkinson′s disease (PD), which encodes glucocerebrosidase. It is difficult to distinguish PD patients with heterozygous variants of GBA1 ( GBA1-PD) from idiopathic Parkinson′s disease patients, but GBA1-PD tends to progress faster, be more severe, and be more likely to be associated with cognitive impairment and other non-motor symptoms. The pathological mechanism of the increased risk of PD in GBA1 heterozygous variant carriers may be related to autophagy-lysosome dysfunction and mitochondrial dysfunction. Targeted therapy for GBA1 is expected to become a new direction of precision therapy for PD. In this article, the epidemiology and clinical features of GBA1-PD, the possible pathogenesis of GBA1 variation, and the therapeutic strategies for GBA1-PD were elaborated.

Synaptic dysfunction plays an important role in the early stage of frontotemporal dementia (FTD), and there are differences in the pattern of synaptic damage in different genotypes. GRN gene mutations are rare in the Chinese population, and there are no reports of synaptic damage patterns in GRN mutations or semantic variant primary progressive aphasia (svPPA). The synaptic injury characteristics of a patient with svPPA harboring GRN gene mutations, which was characterized by decreased synaptic density in the left frontal, temporal, parietal lobe and contralateral cerebellum were reported in this article. The underlying mechanism of synaptic dysfunction involved in the disease process, and potential targets for future clinical interventions were indicated.

Parkinson′s disease (PD) is the second most common neurodegenerative disease following Alzheimer′s disease. The non-motor symptoms of PD have attracted increasing attention. The occurrence of abnormal blood pressure is related to many factors, including aging, PD related autonomic nerve dysfunction, and drugs for PD treatment,including levodopa, dopamine receptor agonists. Abnormal blood pressure severely limits the clinical use of anti-PD drugs. In order to better understand the relationship between anti-PD drugs and blood pressure in patients with PD. This article summarizes the manifestations of abnormal blood pressure, and analyzes the correlation between anti-PD drugs and blood pressure, summarizes the possible mechanisms of how anti-PD drugs affects the blood pressure in PD.

BACKGROUND AND PURPOSE: The aim of this study was to identify the clinical characteristics and potential mechanisms relevant to pathological proteins in Parkinson's disease (PD) patients who experience fatigue. METHODS: PD patients (n=102) were evaluated using a fatigue severity scale and scales for motor and nonmotor symptoms. The levels of three pathological proteins-α-synuclein oligomer, β-amyloid (Aβ)(1-42), and tau-were measured in 102 cerebrospinal fluid (CSF) samples from these PD patients. Linear regression analyses were performed between fatigue score and the CSF levels of the above-listed pathological proteins in PD patients. RESULTS: The frequency of fatigue in the PD patients was 62.75%. The fatigue group had worse motor symptoms and anxiety, depression, and autonomic dysfunction. The CSF level of α-synuclein oligomer was higher and that of Aβ1-42 was lower in the fatigue group than in the non-fatigue group. In multiple linear regression analyses, fatigue severity was significantly and positively correlated with the α-synuclein oligomer level in the CSF of PD patients, after adjusting for confounders. CONCLUSIONS: PD patients experience a high frequency of fatigue. PD patients with fatigue have worse motor and part nonmotor symptoms. Fatigue in PD patients is associated with an increased α-synuclein oligomer level in the CSF.
Anxiety ; Cerebrospinal Fluid ; Depression ; Fatigue* ; Humans ; Linear Models ; Parkinson Disease* ; Weights and Measures

Parkinson′s disease (PD) is a common aging-related neurodegenerative disease of the central nervous system. Its pathogenesis is a series of pathophysiological changes under the interaction of genetic factors and environmental risk factors. Recent studies have shown that the pathophysiologic mechanisms outside the central nervous system, especially inflammation and immune response, may play an important role in the pathogenesis of Parkinson′s disease. This article aims to review the up-to-date research results of the peripheral origin of PD, and to discuss the interplay and activation of the peripheral inflammatory immune system in PD.

Multiple system atrophy (MSA) is a sporadic neurodegenerative disease with insidious onset, and relatively rapid progress in adult. MSA patients may be admitted to different departments of hospital several years before the full manifestation of motor symptoms, because of various non-motor symptoms such as urinary disorders, sexual dysfunction, orthostatic hypotension, psychic symptoms and sleep disorders. This may delay the diagnosis and treatment of MSA. The review is to improve the understanding of the non-motor symptoms of MSA, which may help to reach more accurate diagnosis and better treatment, and improve the quality of life of patients with MSA.

Disorders of Excessive Somnolence ; Humans ; Parkinson Disease ; complications ; REM Sleep Behavior Disorder ; therapy ; Restless Legs Syndrome ; therapy ; Sleep Apnea, Obstructive ; therapy ; Sleep Wake Disorders ; therapy